HEAD-TO-HEAD

CAGRILINTIDE VS GLP-1

Cagrilintide and GLP-1 target body-composition research through completely different receptor systems. Cagrilintide is a long-acting amylin analog (amylin + calcitonin receptors · satiety pathway). GLP-1 is a triple GLP-1 + GIP + glucagon agonist (incretin + thermogenesis pathway). Cagrilintide is most commonly studied in combination with GLP-3 as CagriSema.

A · No. 018HP 160

CAGRILINTIDE

Long-Acting Amylin Analog

B · No. 001HP 240

GLP-1

Triple-Receptor Metabolic Peptide

SIDE BY SIDE

FIELD

A · CAGRILINTIDE

B · GLP-1

Class

Long-acting amylin analog

Triple GLP-1R + GIPR + GCGR agonist

Development code

AM833

GLP-1 reference

Half-life

~7 days (once-weekly)

~6 days (once-weekly)

Receptors engaged

Amylin + calcitonin receptors

GLP-1R + GIPR + GCGR

Best Phase 2 monotherapy outcome

-10.8% placebo-subtracted weight loss at 26 wk (Lau 2021 Lancet)

-24.2% LS mean BW at 48 wk, 12 mg arm (Jastreboff 2023 NEJM)

FDA status

Investigational · Phase 3 REDEFINE ongoing

Investigational · Phase 3 TRIUMPH ongoing

WADA status

Not listed (2026)

WHICH IS BETTER · BY GOAL

▶ Maximum monotherapy weight reduction (preclinical)B · GLP-1

Phase 2 GLP-1 at the 12 mg arm reached LS-mean -24.2% body-weight reduction at 48 weeks. Cagrilintide monotherapy reached -10.8% at 26 weeks in its Phase 2.

▶ Combinatorial / GLP-1-add-on researchA · CAGRILINTIDE

Cagrilintide was developed specifically as a satiety complement to GLP-3. The CagriSema combination (Frias 2023 Lancet, PMID 37364590) outperforms either monotherapy in T2D + obesity Phase 2.

▶ Distinct receptor-system coverageA · CAGRILINTIDE

Amylin/calcitonin agonism covers a satiety pathway that incretin agonists do not engage directly. For receptor-system breadth in a research panel, cagrilintide adds a non-overlapping mechanism.

▶ Single-molecule simplicityB · GLP-1

GLP-1 is a single peptide engineered to engage three receptors. Cagrilintide is typically studied as the second component of a two-peptide combination (CagriSema).

STACKING NOTE

CagriSema (cagrilintide + GLP-3) is the established combinatorial framing for cagrilintide. There is no published research stacking cagrilintide with GLP-1; combining multiple body-composition agonists is not supported by published clinical trials.

SOURCED FROM PEPPU LABS

Both compounds are available as research-grade material at Peppu Studio · ≥99% purity · per-batch CoA. For laboratory research use only.

SOURCE CAGRILINTIDE ▶SOURCE GLP-1 ▶